



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 561 073 A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 92307700.2

(51) Int. Cl.5: **A61K 31/557, // (A61K31/557,  
31:135,31:34,31:47,31:535)**

(22) Date of filing: 24.08.92

(30) Priority: 19.03.92 JP 63316/92

(71) Applicant: R-TECH UENO, LTD.  
4-8, 2-chome, Koralbashi, Chuo-ku  
Osaka-shi, Osaka-fu(JP)

(43) Date of publication of application:  
22.09.93 Bulletin 93/38

(72) Inventor: Ueno, Ryuji  
7-29, Misaku-cho  
Nishinomiya-shi, Hyogo-ken(JP)  
Inventor: Kuno, Sachiko  
4-15-29-343, Mita  
Minato-ku, Tokyo-to(JP)

(64) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC  
NL PT SE

(74) Representative: Atkinson, Peter Birch et al  
Marks & Clerk Suite 301 Sunlight House  
Quay Street  
Manchester M3 3JY (GB)

(54) Treatment of ocular hypertension with beta-blockers and derivatives of protanoic acid.

(57) An agent for the treatment of ocular hypertension, comprising (a) a  $\beta$ -adrenergic blocker to be administered at the enhancement phase of aqueous humor production and (b) a prostanic acid compound to be administered at the suppression phase of aqueous humor production, the component (a) and (b) are contained in separate dosage forms.

EP 0 561 073 A1

BACKGROUND OF THE INVENTION1. Field of the Invention

5 The present invention relates to the treatment of ocular hypertension with alternate administration of (a) a  $\beta$ -adrenergic blocker and (b) a prostanoic acid compound with an improved efficiency.  
 a The compounds used as the component (b) in the present invention are prostaglandin analogues.

2. Information of Prior Art


10 It is well known that the production and effluence of the aqueous humor, which are the important factors for the circulation of the aqueous humor, and hence the intraocular pressure as the results thereof, vary with the circadian rhythm. Generally, in humans, the phase in which the aqueous humor production enhances is the daytime, during which the production of the aqueous humor is facilitated and the intraocular pressure rises. On the other hand, the phase in which the aqueous humor production suppresses is the night, during which the production of the aqueous humor is inhibited and the intraocular pressure falls. In contrast, in rabbits, the phase in which the aqueous humor production enhances is the night and the phase in which the aqueous humor production supresses is the daytime.

This circadian rhythm of the intraocular pressure is observed not only in healthy humans but also in 20 subjects of ocular hypertension such as with glaucoma and a possibility that a relatively big variation in the intraocular pressure of hypertensive subjects may be an aggravating factor to the condition of disease has been noted. Accordingly, there is a continuous need for the development of an improved method for treatment of ocular hypertension in which the intraocular pressure is effectively controlled taking the circadian rhythm of ocular tension in the hypertensive subjects into consideration.

25 The  $\beta$ -adrenergic blockers are the most widely used drugs for the treatment of glaucoma and ocular hypertension. In a report studying a relation between the circadian rhythm of intraocular pressure and the ocular hypotensive activity of Timolol, a  $\beta$ -adrenergic blocker, it was observed that the activity of Timolol was significant in the enhancement phase of aqueous humor production, i.e. daytime in humans and night in rabbits, but negligible in the suppression phase of aqueous humor production, i.e. night in humans and daytime in rabbits. This fact indicates that there may be a possibility in which apparent (or observable) 30 effect of  $\beta$ -adrenergic blockers such as Timolol is high at the enhancement phase of aqueous humor production and low at the suppression phase of aqueous humor production. However, in view of the facts that most of cause for the ocular hypertension lies in the inhibition of effluence of the aqueous humor and that controlling of the ocular hension is important for the treatment of ocular hypertension also in the 35 suppression phase of aqueous humor production, it is considered that treating the ocular hypertension with a  $\beta$ -adrenergic blocker only is insufficient.

Prostanoic acid refers to the basic skeleton, shown by the formula below, as the common structural feature of the naturally occurring prostaglandins (hereinafter, prostaglandins are referred to as PGs).

40



45 50 The primary PGs are classified based on the structural feature of the five-membered cycle moiety into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs, PGIs and PGJs, and also on the presence or absence of unsaturation and oxidation in the chain moiety as:

Subscript 1 13,14-unsaturated-15-OH

Subscript 2 5,6- and 13,14-diunsaturated-15-OH

55 Subscript 3 5,6- 13,14- and 17, 18-triunsaturated-15-OH

Further, PGFs are sub-classified according to the configuration of hydroxy group at position 9 into  $\alpha$ - (hydroxy group being in the alpha configuration) and  $\beta$ - (hydroxy group being in the beta configuration).

The fact that the above compounds under item (b) have ocular hypotensive activity has been known by Japanese Patent Publication No. A-108/1990. It has also been described in Japanese Patent Publication No. A-313728/1988, page 7, column 3, line 7 from bottom to page 8, column 4, line 4, that a combination of PGF<sub>2α</sub> isopropyl ester and Timolol (an agent for treating glaucoma) may be advantageous because the 5 ocular hypotensive activity of the former is not inhibited by a β-adrenergic blocker such as the latter. Furthermore, a synergistic combination of a β-adrenergic blocker and a 13,14-dihydro-15-keto-PG is described in EP-A-458590 (Nov. 27, 1991). Such description, however, does not suggest that an alternate use of the β-adrenergic blocker and the component (b) in the present invention gives an improved results.

After an extensive study the present inventor has surprisingly discovered that the prostanoic acid 10 compounds exhibit a significant ocular hypotensive activity at the suppression phase of aqueous humor production in which the β-adrenergic blockers such as Timolol can hardly exhibit the ocular hypotensive activity.

#### SUMMARY OF THE INVENTION

15 In a first aspect, the present invention provides a method for the treatment of ocular hypertension which comprises ocularly administering, to a subject in need of such treatment,

- (a) a β-adrenergic blocker at the enhancement phase of aqueous humor production, and
- (b) a prostanoic acid compound at the suppression phase of aqueous humor production, in an amount 20 effective in treatment of ocular hypertension.

In a second aspect, the present invention provides an agent for the treatment of ocular hypertension, for alternate administration with a β-adrenergic blocker to be administered at the enhancement phase of aqueous humor production, comprising a prostanoic acid compound in an amount effective in treatment of ocular hypertension to be administered at the suppression phase of aqueous humor production.


25 In a third aspect, the present invention provides an agent for the treatment of ocular hypertension, for alternate administration with a prostanoic acid compound to be administered at the suppression phase of aqueous humor production, comprising a β-adrenergic blocker in an amount effective in treatment of ocular hypertension to be administered at the enhancement phase of aqueous humor production.

In a fourth aspect, the present invention provides an agent for the treatment of ocular hypertension, 30 comprising (a) a β-adrenergic blocker to be administered at the enhancement phase of aqueous humor production and (b) a prostanoic acid compound to be administered at the suppression phase of aqueous humor production, the component (a) and (b) are contained in an amount effective in treatment of ocular hypertension in separate dosage forms.

In a fifth aspect, the present invention provides a package for the treatment of ocular hypertension, 35 comprising a β-adrenergic blocker and a prostanoic acid compound in an amount effective in treatment of ocular hypertension with an indication for administering the β-adrenergic blocker at the enhancement phase of aqueous humor production and administering the prostanoic acid compound at the suppression phase of aqueous humor production.

#### 40 DETAILED DESCRIPTION OF THE INVENTION

The β-adrenergic blockers used as the component (b) in the present invention refer to agents capable of blocking the β-adrenergic receptor. Typical examples of such agents are relatively less selective β-adrenergic receptor blocking agents which are represented by the following formula:



wherein A is an aromatic group and R is hydrogen atom or methyl.

The above group A includes 4-morpholino-1,2,5-thiadiazol-3-yl, 2-acetylbenzofuran-7-yl, 1,2,3,4-tetrahydro-2-oxo-quinolines-5-yl. Preferred compounds include Timolol, Befunolol, Betaxolol, Levabunolol, Carteolol and pharmaceutically acceptable salts thereof such as inorganic salts, e.g. hydrochloride or organic salts, e.g. maleate.

50 The term prostanoic acid compound refers to a compound (or derivative) in which one or more atom or group (or moiety) in the prostanoic acid shown by the formula (A) is replaced by other atom or group or eliminated. Such derivatization includes the modifications known in the synthetic PG analogues such as those shown below and other modifications. The preferred prostanoic acid compounds have the ocular hypotensive activity and particularly aqueous humor effluence enhancing activity.

Nomenclature

Nomenclature of the prostanoic acid compounds herein uses the numbering system of prostanoic acid represented in formula (A) shown above.

5 While formula (A) shows a basic skeleton having twenty carbon atoms, the compounds used in the present invention are not limited to those having the same number of carbon atoms. The carbon atoms in Formula (A) are numbered 2 to 7 on the  $\alpha$ -chain starting from the  $\alpha$ -carbon atom adjacent to the carboxylic carbon atom which is numbered 1 and towards the five-membered ring, 8 to 12 on the said ring starting from the carbon atom on which the  $\alpha$ -chain is attached, and 13 to 20 on the  $\omega$ -chain starting from the 10 carbon atom adjacent to the ring. When the number of carbon atoms is decreased in the  $\alpha$ -chain, the number is deleted in order starting from position 2 and when the number of carbon atoms is increased in the  $\alpha$ -chain, compounds are named as substituted derivatives having respective substituents at position 1 in place of carboxy group (C-1). Similarly, when the number of carbon atoms is decreased in the  $\omega$ -chain, the number is deleted in order starting from position 20 and when the number of carbon atoms is increased in the  $\omega$ -chain, compounds are named as substituted derivatives having respective substituents at position 20. 15 Stereochemistry of the compounds is the same as that of above formula (A) unless otherwise specified.

The above formula expresses a specific configuration which is the most typical one, and in this specification compounds having such a configuration are expressed without any specific reference to it.

In general, PGDs, PGEs and PGFs have a hydroxy group on the carbon atom at position 9 and/or 20 but the compounds used in the present invention includes PGs having a group other than a hydroxyl group at position 9 and/or 11. Such PGs are referred to as 9-dehydroxy-9-substituted-PG compounds or 11-dehydroxy-11-substituted-PG compounds.

As stated above, nomenclature of the prostanoic acid compounds is based upon the prostanoic acid. These compounds, however, can also be named according to the IUPAC naming system. For example, 25 13,14-dihydro-15-keto-16R,S-fluoro- PGE<sub>2</sub> is (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(4R,S)-fluoro-3-oxo-1-octyl]-5-oxocyclopentyl]-hept-5-enoic acid. 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-11R-methyl-PGE<sub>2</sub> methyl ester is methyl (Z)-7-[(1R,2R,3R)-3-methyl-2-[3-oxo-1-decyl]-5-oxocyclopentyl]-hept-5-enoate. 13,14-dihydro-6,15-diketo-19-methyl-PGE<sub>2</sub> ethyl ester is ethyl 7-[(1R,2S,3S)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxocyclopentyl]-6-oxoheptanoate. 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2a</sub> isopropyl ester is isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxo-1-decyl)-cyclopentyl]-hept-5-enoate. 30 13,14-dihydro-15-keto-20-methyl-PGF<sub>2a</sub> methyl ester is methyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxo-1-nonyl)-cyclopentyl]-hept-5-enonate.

Preferred Compounds

35 Preferred prostanoic acid derivatives used in the present invention are those having an oxo group at position 15 of the prostanoic acid in place of the hydroxy group as a feature. These derivatives may have a single bond (15-keto-PG<sub>1</sub> compounds), a double bond (15-keto-PG<sub>2</sub> compounds) between positions 5 and 6, or two double bonds (15-keto-PG<sub>3</sub> compounds) between positions 5 and 6 as well as positions 17 and 18.


40 Examples of substitution products or derivatives include pharmaceutically or physiologically acceptable salts and esters at the carboxy group at the alpha chain, unsaturated derivatives having a double bond or a triple bond between positions 2 and 3 or positions 5 and 6, respectively, substituted derivatives having substituent(s) on carbon atom(s) at position 3, 6, 16, 17, 19 and/or 20 and compounds having lower alkyl or a hydroxy (lower) alkyl group at position 9 and/or 11 in place of the hydroxy group, of the above PGs.

45 Examples of substituents present in preferred compounds are as follows: Substituents on the carbon atom at position 3, 17 and/or 19 include lower alkyl, for example, C<sub>1-4</sub> alkyl, especially methyl and ethyl. Substituents on the carbon atom at position 16 include lower alkyl e.g. methyl, ethyl etc., hydroxy and halogen atom e.g. chlorine, fluorine, aryloxy e.g. trifluoromethylphenoxy, etc. Substituents on the carbon atom at position 20 include saturated and unsaturated lower alkyl e.g. C<sub>1-4</sub> alkyl, lower alkoxy e.g. C<sub>1-4</sub> 50 alkoxy and lower alkoxy (lower) alkyl e.g. C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl. Substituents on the carbon atom at position 6 include oxo group forming carbonyl. Stereochemistry of PGs having hydroxy, lower alkyl or lower (hydroxy) alkyl substituent on the carbon atom at position 9 and/or 11 may be alpha, beta or mixtures thereof.

Said derivatives may have an alkoxy, phenoxy or phenyl group at the end of the omega chain where the 55 chain is shorter than the primary PGs.

Especially preferred compounds are those having a lower alkyl such as methyl, ethyl, etc. at position 20.

A group of preferred compounds used in the present invention has the formula



wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C=C-, Z is

20

wherein R<sub>3</sub> is lower alkyl or acyl,

R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl,

25 R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

In the above formula, the term "unsaturated" in the definitions for R<sub>1</sub> and R<sub>2</sub> is intended to include at least one and optionally more than one double bond and/or triple bond isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to usual nomenclature, an unsaturation between two serial positions is represented by denoting the lower number of said two positions, and an unsaturation between two distal positions is represented by denoting both of the positions. Preferred unsaturation is a double bond at position 2 and a double or triple bond at position 5.

30 The term "lower or medium aliphatic hydrocarbon residue" or "medium aliphatic hydrocarbon residue" refers to a straight or branched chain hydrocarbyl group having 1 to 14 carbon atoms or 5 to 14 carbon atoms, respectively, (for a side chain, 1 to 3 carbon atoms being preferred) and preferably 2 to 8 carbon atoms for R<sub>1</sub> and 6 to 9 carbon atoms for R<sub>2</sub>.

35 The term "halo" denotes fluoro, chloro, bromo and iodo.

The term "lower" throughout the specification is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.

40 The term "lower alkyl" as a group or a moiety in hydroxy(lower)alkyl, monocyclic aryl(lower) alkyl, monocyclic aroyl(lower)alkyl or halo(lower)alkyl includes saturated and straight or branched chain hydrocarbon radicals containing 1 to 6, carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.

The term "lower alkoxy" refers to the group lower-alkyl-O- wherein lower alkyl is as defined above.

45 The term "hydroxy(lower)alkyl" refers to lower alkyl as defined above which is substituted with at least one hydroxy group, e.g. hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-1-hydroxyethyl.

The term "lower alkanoyloxy" refers to a group of the formula: RCO-O- wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, e.g. acetyl.

50 The term "cyclo(lower)alkyl" refers to a cyclic group formed by cyclization of a lower alkyl group as defined above.

The term "aryl" includes unsubstituted or substituted aromatic carbocyclic or heterocyclic (preferably monocyclic) groups, e.g. phenyl, tolyl, xylol and thiienyl. Examples of substituents are halo and halo(lower)-alkyl wherein halo and lower alkyl being as defined above.

The term "aryloxy" refers to a group of the formula: ArO- wherein Ar is aryl as defined above.

55 Suitable "pharmaceutically acceptable salts" includes conventional non-toxic salts, and may be a salt with an inorganic base, for example an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, a salt with an organic base, for example, an amine salt (e.g. methylamine salt, dimethylamine salt, cyclohexylamine salt,

benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)ethane salt, monomethyl-monoethanolamine salt, procaine salt, caffeine salt, etc.), a basic amino acid salt (e.g. arginine salt, lysine salt, etc.), tetraalkyl ammonium salt and the like. These salts can be prepared by the conventional process, for example from the corresponding acid and base or by salt interchange.

Examples of the "pharmaceutically acceptable esters are aliphatic esters, for example, lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, 1-cyclopropylethyl ester, etc., lower alkenyl ester e.g. vinyl ester, allyl ester, etc., lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc., hydroxy(lower) alkyl ester e.g. hydroxyethyl ester, lower alkoxy(lower)-alkyl ester e.g. methoxymethyl ester, 1-methoxyethyl ester, etc., and aromatic esters, for example, optionally substituted aryl ester e.g. phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-dimethoxyphenyl ester, benzamidophenyl ester etc., aryl(lower)alkyl ester e.g. benzyl ester, trityl ester, benzhydryl ester, etc. These esters may be prepared by conventional esterification starting from the corresponding acid and alcohol or ester exchange.


Preferred examples of A include -COOH, -COOCH<sub>3</sub>, -COOCH<sub>2</sub>CH<sub>3</sub> and -COOCH(CH<sub>3</sub>)<sub>2</sub>.

The configuration of the ring and the  $\alpha$ - and/or omega chain in the above formula (I) may be the same as or different from that in the primary PGs. However, the present invention also includes a mixture of a compound having a primary configuration and that of an unprimary configuration.

A group of more preferred compounds used in the present invention has the formula

20

25



30

wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C=C-, R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue having 5 or more carbon atoms in the main or straight chain moiety which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

40 Examples of the typical compounds of the present invention are 15-keto-20-loweralkyl-PGA-Fs and their  $\Delta^2$ -derivatives, 3R,S-methyl-derivatives, 6-oxo-derivatives, 5R,S-fluoro-derivatives, 5,5-difluoro-derivatives, 16R,S-methyl-derivatives, 16,16-dimethyl-derivatives, 16R,S-fluoro-derivatives, 16,16-difluoro-derivatives, 17S-methyl-derivatives, 17R,S-fluoro-derivatives, 17,17-difluoro-derivatives and 19-methyl-derivatives.

45 The compounds having 15-keto group may be in the keto-hemiacetal equilibrium by forming a hemiacetal between hydroxy group at position 11 and ketone at position 15.

50 The proportion of both tautomeric isomers, when present, varies depending on the structure of the rest of the molecule or kind of any substituent present and, sometimes, one isomer may predominantly be present in comparison with the other. However, in this invention, it is to be appreciated that the compounds used in the invention include both isomers. Further, while the compounds used in the invention may be represented by a structure or name based on keto-form regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend elimination of the hemiacetal type of compounds.

55 In the present invention, any of the individual tautomeric isomers, a mixture thereof, or optical isomers, a mixture thereof, a racemic mixture, and other isomers such as steric isomers can be used in the same purpose.

Some of the compounds used in the present invention may be prepared by the method disclosed in Japanese Patent Publications (unexamined) No. A-108/1990 and A-96528/1990.


Alternatively, these compounds may be prepared by a process analogous to that described in the above publications in combination with the known synthetic method for the five-membered ring moiety.

In the process for preparing 13,14-dihydro-15-keto-compound:

5 A commercially available (-)-Corey lactone, which is used as a starting material, is subjected to Collins oxidation to give an aldehyde. The aldehyde is allowed to react with dimethyl (2-oxoalkyl)phosphonate anion to give an  $\alpha,\beta$ -unsaturated ketone, and the resultant is reduced to ketone. The carbonyl group of the ketone is allowed to react with a diol to give a ketal, thereby protected, then a corresponding alcohol is obtained by elimination of the phenylbenzoyl group, and the resulting hydroxy group is protected with dihydropyran to give a tetrapyranyl ether. Thus, precursors of PGs wherein the  $\omega$ -chain is 13,14-dihydro-15-keto-alkyl can be obtained.

10 Using the above tetrapyranyl ether as a starting material, 6-keto-PG<sub>1</sub>s of the formula:

15




20

may be obtained as follows:

25 The tetrapyranyl ether is reduced using diisobutyl aluminium hydride and the like to give a lactol, which is allowed to react with a ylide obtained from (4-carboxybutyl)triphenylphosphonium bromide, and the resultant is subjected to esterification followed by cyclization, combining the 5,6-double bond and the C-9 hydroxyl group with NBS or iodine, providing a halide. The resultant is subjected to dehydrohalogenation with DBU and the like to give a 6-keto compound, which is subjected to Jones oxidation followed by deprotection to give the objective compound.

Further, PG<sub>2</sub>s of the formula:

30




35

may be obtained as follows:

The above tetrapyranyl ether is reduced to the lactol, which is allowed to react with a ylide obtained from (4-carboxybutyl)triphenylphosphonium bromide to give a carboxylic acid. The resultant is subjected to esterification followed by Jones oxidation and deprotection to give the objective compound.


40 In order to obtain PG<sub>1</sub>s of the formula:

45




using the above tetrapyranyl ether as a starting material, in the same manner as PG<sub>2</sub> of the formula:

50




55 the 5,6-double bond of the resulting compound is subjected to catalytic reduction followed by deprotection. To prepare 5,6-dehydro-PG<sub>2</sub>s containing a hydrocarbon chain of the formula:



5

a monoalkyl copper complex or a dialkyl copper complex of the formula:



15

is subjected to 1,4-addition with 4R-t-butyldimethylsilyloxy-2-cyclopenten-1-one, and the resulting copper enolate is seized with 6-carboalkoxy-1-iodo-2-hexyne or a derivative thereof.

PGs containing a methyl group instead of a hydroxy group at the C-11 position may be obtained as follows:

PGA obtained by Jones oxidation of the hydroxy group at the C-9 position of the 11-tosylate is allowed to react with a dimethyl copper complex to give 11-dehydroxy-11-methyl-PGE. Alternatively, an alcohol obtained after elimination of p-phenylbenzoyl group is converted to a tosylate. An unsaturated lactone obtained by DBU treatment of the tosylate is converted to a lactol. After introduction of an  $\alpha$ -chain using Wittig reaction, the resulting alcohol (C-9 position) is oxidized to give PGA. PGA is allowed to react with dimethyl copper complex to give 11-dehydroxy-11-methyl-PGE. The resultant is reduced using sodium borohydride and the like to give 11-dehydroxy-11-methyl-PGF.

PGs containing a hydroxymethyl group instead of a hydroxyl group at the C-11 position is obtained as follow: 11-dehydroxy-11-hydroxymethyl-PGE is obtained by a benzophenone-sensitized photoaddition of methanol to PGA. The resultant is, for example, reduced using sodium borohydride to give 11-dehydroxy-11-hydroxymethyl-PGF.

16-Fluoro-PGs may be obtained using dimethyl (3-fluoro-2-oxoalkyl)phosphonate anion in the preparation of an  $\alpha,\beta$ -unsaturated ketone. Similarly, 19-methyl-PGs may be obtained using a dimethyl (6-methyl-2-oxoalkyl)phosphonate anion.

35 The preparations in the present invention are not construed to be limited to them, and suitable means for protection, oxidation, reduction and the like may be employed.

Examples of the preparation of the prostanic acid compounds are described in the Japanese Patent Publications (unexamined) No. A-151552/1989, A-108/1990, A-96528/1990 and A-96529/1990.

The  $\beta$ -adrenergic blockers and the prostanic acid compounds used in the present invention can be used for the treatment of various disease and conditions of humans and animals in which lowering of ocular pressure is desirous and are usually administered systemically or topically by, for example, ophthalmic, oral, intravenous, subcutaneous, rectal administration etc.

As used herein, the term "treatment" or "treating" refers to any means of control of a disease in a mammal, including preventing the disease, curing the disease, relieving the disease and arresting or relieving the development of the disease.

While the dosage varies depending on the kind, age, weight, condition of the patient, such as humans or animals, severity of the disease, purpose of the treatment, judgement of the physician and route or period of administration, usually a satisfactory effect is obtained within the range of 0.01-500  $\mu$ g/eye of the  $\beta$ -adrenergic blocker and 0.001-500 mg/kg of the prostanic acid compound.

50 The agents used in the present invention can be administered in the form of a pharmaceutical composition containing the active components and optionally other ingredients, such as carrier, diluent or excipient.

Such composition includes liquids such as ophthalmic solution, emulsion, dispersion etc. and semisolids such as gel, ointment etc.

55 Diluents for the aqueous solution or suspension include, for example, distilled water and physiological saline. Diluents for the nonaqueous solution and suspension include, for example, vegetable oils e.g. olive oil, liquid paraffine, mineral oil, and propylene glycol and p-octyldecanol. The composition may also contain isotonicization agents such as sodium chloride, boric acid, sodium citrate, etc. to make isotonic with

the lacrimal fluid and buffering agents such as borate buffer, phosphate buffer, etc. to maintain pH about 5.0 to 8.0. Further, stabilizers such as sodium sulfite, propylene glycol, etc., chelating agents such as sodium edetate, etc., thickeners such as glycerol, carboxymethylcellulose, carboxyvinyl polymer, etc. and preservatives such as methyl paraben, propyl paraben, etc. may also be added. these can be sterilized e.g. by 5 passing through a bacterial filter or by heating.

The ophthalmic ointment may contain vaseline, Plastibase, Macrogol, etc. as a base and surfactant for increasing hydrophilicity. It may also contain gelling agents such as carboxymethylcellulose, methylcellulose, carboxyvinyl polymer, etc.

In addition, the composition may contain antibiotics such as chloramphenicol, penicillin, etc. in order to 10 prevent or treat bacterial infection.

These composition may be packaged with an indication for administration. Such indication may be printing on package box, a bottle, a label, a separate paper sheet etc.

A more complete understanding of the present invention can be obtained by reference to the following Preparation Examples, Formulation Examples and Test Examples which are provided herein for purpose of 15 illustration only and are not intended to limit the scope of the invention.

### Preparations

Preparations of 13,14-dihydro-15-keto-20-ethyl-PGA<sub>2</sub> isopropyl ester, 13,14-dihydro-15-keto-20-ethyl-PGE<sub>2</sub> 20 isopropyl ester and 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester (cf. Preparation chart I):

1) Preparation of 1S-2-oxa-3-oxo-6R-(3-oxo-1-trans-decanyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo [3.3.0]-octane (3):

Commercially available (-)-Corey lactone (1) (7 g) was subjected to Collins oxidation in dichloromethane to give aldehyde (2). The resultant was allowed to react with dimethyl (2-oxononyl)-25 phosphonate (4.97 g) anion to give 1S-2-oxa-3-oxo-6R-(3,3-ethylenedioxy-1-trans-decanyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo[3.3.0]-octane (3).

2) Preparation of 1S-2-oxa-3-oxo-6R-(3-oxodecyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo[3.3.0]-octane (4):

Unsaturated ketone (3) (7.80 g) was reduced in ethyl acetate (170 ml) using 5% Pd/C under 30 hydrogen atmosphere. The product obtained after the usual work-up (4) was used in the following reaction.

3) Preparation of 1S-2-oxa-3-oxo-6R-(3,3-ethylenedioxy-decyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo-[3.3.0]-octane (5):

Saturated ketone (4) was converted to ketal (5) in dry benzene (150 ml) using ethylene glycol and p-toluenesulfonic acid (catalytic amount).

4) Preparation of 1S-2-oxa-3-oxo-6R-(3,3-ethylenedioxy-decyl)-7R-hydroxy-cis-bicyclo[3.3.0]-octane (6):

To a solution of ketal (5) in absolute methanol (150 ml) was added potassium carbonate (2.73 g). The mixture was stirred overnight at room temperature. After neutralization with acetic acid, the resultant was concentrated under reduced pressure. The resulting crude product was extracted with ethyl acetate. The organic layer was washed with a dilute aqueous solution of sodium bicarbonate and a saline, and 40 dried. The crude product obtained after evaporation was chromatographed to give alcohol (6). Yield: 3.31 g

5) Preparation of lactol (7)

Alcohol (6) (0.80 g) was reduced in dry toluene (8 ml) using DIBAL-H at -78 °C to give lactol (7).

6) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2α</sub> (8):

A DMSO solution of lactol (7) was added to ylide prepared from (4-carboxybutyl)-45 triphenylphosphonium bromide (3.65 g). The reaction mixture was stirred overnight to give carboxylic acid (8).

7) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2α</sub> isopropyl ester (9):

Carboxylic acid (8) was converted to 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2α</sub> isopropyl ester (9) using DBU and isopropyl iodide in acetonitrile.

Yield: 0.71 g

8) Preparation of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester (10):

13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2α</sub> isopropyl ester (9) (0.71 g) was kept in acetic acid/THF/water (3/1/1) at 40 °C for 3 hours. The crude product obtained after concentration under 55 reduced pressure was chromatographed to give 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester (10).

Yield: 0.554 g

9) Preparation of 13,14-dihydro-15-keto-20-ethyl-PGA<sub>2α</sub> isopropyl ester (12):

A solution of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester (10) (0.125 g) and p-toluenesulfonyl chloride (0.112 g) in pyridine (5 ml) was maintained at 0 °C for 2 days. According to the usual work-up, tosylate (11) was obtained.

5      Tosylate (11) was subjected to Jones oxidation in acetone (8 ml) at -25 °C. The crude product obtained after the usual work-up was chromatographed to give 13,14-dihydro-15-keto-20-ethyl-PGA<sub>2α</sub> isopropyl ester (2).

Yield: 0.060 g

10) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGF<sub>2α</sub> isopropyl ester (13):

13, 14-dihydro-15, 15-ethylenedioxy-20-ethyl-PGF<sub>2α</sub> isopropyl ester (9) (3.051 g) was dissolved in dry N,N-dimethylformamide (25 ml), t-butyldimethylsilyl chloride (1.088 g) and imidazole (0.49 g) was added thereto. The resultant was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was chromatographed to give 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGF<sub>2α</sub> isopropyl ester (13).

15      Yield: 2.641 g

11) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGE<sub>2</sub> isopropyl ester (14):

13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGF<sub>2α</sub> isopropyl ester (13) (1.257 g) was subjected to Jones oxidation at -40 °C. After the usual work-up, the resulting crude product was chromatographed to give 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGE<sub>2</sub> isopropyl ester (14).

Yield: 1.082 g

12) Preparation of 13,14-dihydro-15-keto-20-ethyl-PGE<sub>2</sub> isopropyl ester (15):

25      To a solution of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGE<sub>2α</sub> isopropyl ester (14) in acetonitrile was added hydrofluoric acid (46% aqueous solution). The mixture was stirred at room temperature for 40 minutes. The crude products obtained after usual work-up was chromatographed to give 13,14-dihydro-15-keto-20-ethyl-PGE<sub>2</sub> isopropyl ester (15).

Yield: 0.063 g (97%)

30

35


40

45


50

55

## Preparation Chart



### Preparation Chart (continued)



### Formulation Example 1

Timolol maleate 0.1 g  
Physiological saline q.s. to 100 ml

Formulation Example 2		
13,14-dihydro-15-keto-20-ethyl-PGF <sub>2α</sub> isopropyl ester	0.01 g	
Nonionic Surfactant	1.0 g	
Physiological saline	q.s. to 100 ml	

5

Test Example 1

10 Hypotensive effect of Timolol was evaluated in the enhancement phase of aqueous humor production and the suppression phase of aqueous humor production of rabbits. Since the circadian rhythm of rabbits, different from that of humans, has the enhancement phase of aqueous humor production at night and the suppression phase of aqueous humor production at daytime, the following two experiments were performed.

15 (1) Enhancement phase of aqueous humor production:

White rabbits (n=8) were used in the experiment of intraocular pressure measurement after keeping under the environmental conditions including a light and darkness cycle consisting of a light period from 21:00 to 9:00 and a dark period from 9:00 to 21:00 for more than one week. In the experiment, 35 µl of a 0.5% Timolol eyedrop (Trademark: Timoptol) was administered to one eye at 11:00 (dark time). The ocular tension was measured immediately before and 1 hour after the administration and the difference between the obtained two values was expressed as decrease in intraocular pressure (ΔIOP).

25 (2) Suppression phase of aqueous humor production:

White rabbits (n=12) were used in the experiment of intraocular pressure measurement after keeping under the environmental conditions including a light and darkness cycle consisting of a light period from 8:00 to 20:00 and a dark period from 20:00 to 8:00 for more than one week. In the experiment, 35 µl of a 0.5% Timolol eyedrop (Trademark: Timoptol) was administered to one eye at 10:00 (light time). The ocular tension was measured immediately before and 3 hours after the administration and the difference between the obtained two values was expressed as decrease in intraocular pressure (ΔIOP). The results are shown in Table 1.

35

Table 1

	Enhancement Phase*	Suppression Phase*
ΔIOP (mmHg)	6.4±1.0	2.5±0.8

40

\* Production of aqueous humor

45

Then, the procedure of the experiment (2) was repeated except that a 0.12% eye drop of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester was used in place of the 0.5% Timolol eye drop. The results are shown in Table 2.

45

Table 2

	Suppression Phase*
ΔIOP (mmHg)	7.1±0.7

\* See footnote of Table 1.

55

Test Example 2

A 0.5% Timolol eye drop was intraocularly administered to subjects of glaucoma (n=8) twice (morning and evening) a day for 4 weeks. Differences in intraocular pressure were measured as in Test Example 1

and expressed as decrease in intraocular pressure ( $\Delta$ IOP). The results are shown in Table 3.

Table 3

	Enhancement Phase* (11:00)	Suppression Phase* (19:00)
$\Delta$ IOP (mmHg)	2.9 $\pm$ 0.8	0.4 $\pm$ 0.7

\* See footnote of Table 1.

Separately, the above experiment was repeated using subjects of glaucoma (n = 10) and administering a 0.12% eye drop of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2 $\alpha$</sub>  isopropyl ester in place of the 0.5% Timolol eye drop and decrease in intraocular pressure ( $\Delta$ IOP) was determined at the suppression phase of aqueous humor production (19:00). The results are shown in Table 4.

Table 4

	Suppression Phase*
$\Delta$ IOP (mmHg)	2.1 $\pm$ 0.3

\* See footnote of Table 1.

## Claims

1. A product for the treatment of ocular hypertension which comprises
  - (a) a  $\beta$ -adrenergic blocker for administration at the enhancement phase of aqueous-humor production, and
  - (b) a prostanoic acid compound for administration at the suppression phase of aqueous-humor production,
 said compounds (a) and (b) being present in amounts effective in treatment of ocular hypertension.
2. The product according to claim 1, wherein the prostanoic acid compound is a prostaglandin compound.
3. The product according to claim 1, wherein the prostanoic acid compound is a prostaglandin F compound.
4. The product according to claim 1, wherein the  $\beta$ -adrenergic blocker is selected from the group consisting of Timolol, Befunolol, Betaxolol, Levobunolol, Carteolol and pharmaceutically acceptable salt thereof.
5. The product according to claim 1 for the treatment of glaucoma.
6. A product for the treatment of ocular hypertension which comprises
  - (a) a  $\beta$ -adrenergic blocker for administration at daytime when the phase of aqueous-humor production is enhancing, and
  - (b) a prostanoic compound for administration at night when the phase of aqueous-humor production is suppressing, said compounds (a) and (b) being present in amounts effective in treatment of ocular hypertension.
7. An agent for the treatment of ocular hypertension, for alternate administration with a  $\beta$ -adrenergic blocker to be administered at the enhancement phase of aqueous-humor production, comprising a prostanoic compound in an amount effective treatment of ocular hypertension to be administered at the suppression phase of aqueous-humor production.
8. An agent for the treatment of ocular hypertension, for alternate administration with a prostanoic compound to be administered at the suppression phase of aqueous-humor production, comprising a  $\beta$ -

adrenergic blocker an amount effective in treatment of ocular hypertension to be administered at the enhancement phase of aqueous-humor production.

9. An agent for the treatment of ocular hypertension comprising (a) a  $\beta$ -adrenergic blocker to be administered at the enhancement phase of aqueous-humor production and (b) a prostanoic acid compound to be administered at the suppression phase of aqueous-humor production, the component (a) and (b) are contained in an amount effective in treatment of ocular hypertension in separate dosage forms.

10. A package for the treatment of ocular hypertension, comprising a  $\beta$ -adrenergic blocker and a prostanoic acid compound in an amount effective in treatment of ocular hypertension with an indication for administering the  $\beta$ -adrenergic blocker to be administered at the enhancement phase of aqueous-humor production and administering the prostanoic acid compound at the suppression phase of aqueous-humor production.

15

20

25

30

35

40

45

50

55



European Patent  
Office

EUROPEAN SEARCH REPORT

Application Number

EP 92 30 7700

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D, X	EP-A-0 458 590 (K.K. UENO SEIYAKU OYO KENKYUJO) *the whole document, especially claim 9* ---	1-10	A61K31/557 //(A61K31/557, 31:135, 31:34, 31:47,31:535)
X	EP-A-0 286 903 (PHARMACIA AB) * column 3, line 14 - column 4, line 15; claims * & JP-A-63 313 728 (...) ---	1-10	
X	ARCH . OPHTHALMOL. vol. 108, no. 8, 1990, pages 1102 - 1105 J. VILLUMSEN 'The effect of adding prostaglandin F2alpha-isopropylester to timolol in patients with open angle glaucoma.' * the whole document * ---	1-10	
X	OPHTHALMOLOGY vol. 98, no. 7, 1991, pages 1079 - 1082 P.-Y. LEE 'Additivity of prostaglandin F2alpha-1-isopropyl ester to timolol in glaucoma patients.' * the whole document * -----	1-10	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A61K
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	17 MAY 1993	ORVIZ DIAZ P.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 561 073 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
24.10.2001 Bulletin 2001/43

(51) Int Cl.7: A61K 31/557  
// (A61K31/557, 31:135, 31:34,  
31:47, 31:535)

(21) Application number: 92307700.2

(22) Date of filing: 24.08.1992

### (54) Treatment of ocular hypertension with beta-blockers and derivatives of prostanoic acid

Behandlung von Augenhochdruck mit Betablockern und Prostansäurederivaten

Traiteme nt de l'hypertension oculaire avec des bêta-bloquants et des dérivés de l'acide prostanoïque

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

(30) Priority: 19.03.1992 JP 6331692

(43) Date of publication of application:  
22.09.1993 Bulletin 1993/38

(73) Proprietor: R-TECH UENO LTD.  
Osaka-shi, Osaka-fu (JP)

(72) Inventors:  
• Ueno, Ryuji  
Nishinomiya-shi, Hyogo-ken (JP)  
• Kuno, Sachiko  
Minato-ku, Tokyo-to (JP)

(74) Representative: Atkinson, Peter Birch et al  
MARKS & CLERK,  
Sussex House,  
83-85 Mosley Street  
Manchester M2 3LG (GB)

(56) References cited:  
EP-A- 0 286 903 EP-A- 0 458 590

- ARCH. OPHTHALMOL. vol. 108, no. 8, 1990,  
pages 1102 - 1105 J. VILLUMSEN 'The effect of  
adding prostaglandin F2alpha-isopropylester to  
timolol in patients with open angle glaucoma.'
- OPHTHALMOLOGY vol. 98, no. 7, 1991, pages  
1079 - 1082 P.-Y. LEE 'Additivity of prostaglandin  
F2alpha-1-isopropylester to timolol in glaucoma  
patients.'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 561 073 B1

**Description****BACKGROUND OF THE INVENTION**5 **1. Field of the Invention**

[0001] The present invention relates to the treatment of ocular hypertension with alternate administration of (a) a  $\beta$ -adrenergic blocker and (b) a prostanoic acid compound with an improved efficiency.

[0002] The compounds used as the component (b) in the present invention are prostaglandin analogues.

10 **2. Information of Prior Art**


[0003] It is well known that the production and effluence of the aqueous humour, which are the important factors for the circulation of the aqueous humour, and hence the intraocular pressure as the results thereof, vary with the circadian rhythm. Generally, in humans, the phase in which the aqueous humour production enhances is the daytime, during which the production of the aqueous humour is facilitated and the intraocular pressure rises. On the other hand, the phase in which the aqueous humour production suppresses is the night, during which the production of the aqueous humour is inhibited and the intraocular pressure falls. In contrast, in rabbits, the phase in which the aqueous humour production enhances is the night and the phase in which the aqueous humour production suppresses is the daytime.

[0004] This circadian rhythm of the intraocular pressure is observed not only in healthy humans but also in subjects of ocular hypertension such as with glaucoma and a possibility that a relatively big variation in the intraocular pressure of hypertensive subjects may be an aggravating factor to the condition of disease has been noted. Accordingly, there is a continuous need for the development of an improved method for treatment of ocular hypertension in which the intraocular pressure is effectively controlled taking the circadian rhythm of ocular tension in the hypertensive subjects into consideration.

[0005] The  $\beta$ -adrenergic blockers are the most widely used drugs for the treatment of glaucoma and ocular hypertension. In a report studying a relation between the circadian rhythm of intraocular pressure and the ocular hypotensive activity of Timolol, a  $\beta$ -adrenergic blocker, it was observed that the activity of Timolol was significant in the enhancement phase of aqueous humour production, i.e. daytime in humans and night in rabbits, but negligible in the suppression phase of aqueous humour production, i.e. night in humans and daytime in rabbits. This fact indicates that there may be a possibility in which apparent (or observable) effect of  $\beta$ -adrenergic blockers such as Timolol is high at the enhancement phase of aqueous humour production and low at the suppression phase of aqueous humour production. However, in view of the facts that most of cause for the ocular hypertension lies in the inhibition of effluence of the aqueous humour and that controlling of the ocular tension is important for the treatment of ocular hypertension also in the suppression phase of aqueous humour production, it is considered that treating the ocular hypertension with a  $\beta$ -adrenergic blocker only is insufficient.

[0006] Prostanoic acid refers to the basic skeleton, shown by the formula below, as the common structural feature of the naturally occurring prostaglandins (hereinafter, prostaglandins are referred to as PGs).

40



50

The primary PGs are classified based on the structural feature of the five-membered cycle moiety into PGAs, PGBs, PGCs, PGDs, PGEs, PGFs, PGGs, PGHs, PGIs and PGJs, and also on the presence or absence of unsaturation and oxidation in the chain moiety as:

55 Subscript 1 - - - 13,14-unsaturated-15-OH

Subscript 2 - - - 5,6- and 13,14-diunsaturated-15-OH

Subscript 3 - - - 5,6- 13,14- and 17,18-triunsaturated-15-OH

Further, PGFs are sub-classified according to the configuration of hydroxy group at position 9 into  $\alpha$ (hydroxy group being in the alpha configuration) and  $\beta$ (hydroxy group being in the beta configuration).

[0007] The fact that the above compounds under item (b) have ocular hypotensive activity has been known by Japanese Patent Publication No. A-108/1990. It has also been described in Japanese Patent Publication No. A-

5 313728/1988, page 7, column 3, line 7 from bottom to page 8, column 4, line 4, that a combination of PGF<sub>2 $\alpha$</sub>  isopropyl ester and Timolol (an agent for treating glaucoma) may be advantageous because the ocular hypotensive activity of the former is not inhibited by a  $\beta$ -adrenergic blocker such as the latter. Furthermore, a synergistic combination of a  $\beta$ -adrenergic blocker and a 13,14-dihydro-15-keto-PG is described in EP-A-458590 (Nov. 27, 1991). Such description, however, does not suggest that an alternate use of the  $\beta$ -adrenergic blocker and the component (b) in the present

10 invention gives improved results.

[0008] Similarly, a synergistic combination of a  $\beta$ -adrenergic blocker and a PGF<sub>2 $\alpha$</sub>  ester is described in EP-A-0 286 903; Ophthalmology, 98 (7), 1991, 1079; and Arch. Ophthalmology 108 (8), 1990, 1102. Although a synergistic relationship between the two agents is shown, the documents do not suggest that alternate use of the two agents gives improved results.

15 [0009] After an extensive study the present inventor has surprisingly discovered that the prostanoic acid compounds exhibit a significant ocular hypotensive activity at the suppression phase of aqueous humor production in which the  $\beta$ -adrenergic blockers such as Timolol can hardly exhibit the ocular hypotensive activity.

## SUMMARY OF THE INVENTION

20 [0010] In a first aspect, the present invention provides the use of a  $\beta$ -adrenergic blocker and of a derivative of prostanoic acid for the manufacture of a therapeutic kit for the concomitant treatment of ocular hypertension, wherein the  $\beta$ -adrenergic blocker is to be administered only in the enhancement phase of aqueous humour production and the derivative of prostanoic acid is to be administered only in the suppression phase of aqueous humour production

25 [0011] In a second aspect the present invention provides the use of a  $\beta$ -adrenergic blocker and of a derivative of prostanoic acid for the manufacture of a therapeutic kit for the concomitant treatment of glaucoma, wherein the  $\beta$ -adrenergic blocker is to be administered only in the enhancement phase of aqueous humour production and the derivative of prostanoic acid is to be administered only in the suppression phase of aqueous humour production.

## DETAILED DESCRIPTION OF THE INVENTION

[0012] The  $\beta$ -adrenergic blockers used in the present invention refer to agents capable of blocking the  $\beta$ -adrenergic receptor. Typical examples of such agents are relatively less selective  $\beta$ -adrenergic receptor blocking agents which are represented by the following formula:



35 wherein A is an aromatic group and R is hydrogen atom or methyl.

40 [0013] The above group A includes 4-morpholino-1,2,5-thiadiazol-3-yl, 2-acetylbenzofuran-7-yl, 1,2,3,4-tetrahydro-2-oxo-quinoline-5-yl. Preferred compounds include Timolol, Befunolol, Betaxolol, Levabunolol, Carteolol and pharmaceutically acceptable salts thereof such as inorganic salts, e.g. hydrochloride or organic salts, e.g. maleate.

45 [0014] The term prostanoic acid compound refers to a compound (or derivative) in which one or more atom or group (or moiety) in the prostanoic acid shown by the formula (A) is replaced by other atom or group or eliminated. Such derivatization includes the modifications known in the synthetic PG analogues such as those shown below and other modifications. The preferred prostanoic acid compounds have the ocular hypotensive activity and particularly aqueous humor effluence enhancing activity.

## Nomenclature

50 [0015] Nomenclature of the prostanoic acid compounds herein uses the numbering system of prostanoic acid represented in formula (A) shown above.

[0016] While formula (A) shows a basic skeleton having twenty carbon atoms, the compounds used in the present invention are not limited to those having the same number of carbon atoms. The carbon atoms in Formula (A) are numbered 2 to 7 on the  $\alpha$ -chain starting from the  $\alpha$ -carbon atom adjacent to the carboxylic carbon atom which is numbered 1 and towards the five-membered ring, 8 to 12 on the said ring starting from the carbon atom on which the  $\alpha$ -chain is attached, and 13 to 20 on the  $\omega$ -chain starting from the carbon atom adjacent to the ring. When the number of carbon atoms is decreased in the  $\alpha$ -chain, the number is deleted in order starting from position 2 and when the

number of carbon atoms is increased in the  $\alpha$ -chain, compounds are named as substituted derivatives having respective substituents at position 1 in place of carboxy group (C-1). Similarly, when the number of carbon atoms is decreased in the  $\omega$ -chain, the number is deleted in order starting from position 20 and when the number of carbon atoms is increased in the  $\omega$ -chain, compounds are named as substituted derivatives having respective substituents at position 20.

5 Stereochemistry of the compounds is the same as that of above formula (A) unless otherwise specified.

[0017] The above formula expresses a specific configuration which is the most typical one, and in this specification compounds having such a configuration are expressed without any specific reference to it.

[0018] In general, PGDs, PGEs and PGFs have a hydroxy group on the carbon atom at position 9 and/or 11 but the 10 compounds used in the present invention includes PGs having a group other than a hydroxyl group at position 9 and/or 11. Such PGs are referred to as 9-dehydroxy-9-substituted-PG compounds or 11-dehydroxy-11-substituted-PG compounds.

[0019] As stated above, nomenclature of the prostanoic acid compounds is based upon the prostanoic acid. These 15 compounds, however, can also be named according to the IUPAC naming system. For example, 13,14-dihydro-15-keto-16R,S-fluoro- PGE<sub>2</sub> is (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(4R,S)-fluoro-3-oxo-1-octyl]-5-oxocyclopentyl]-hept-5-enoic acid. 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-11R-methyl-PGE<sub>2</sub> methyl ester is methyl (Z)-7-[(1R,2R,3R)-3-methyl-2-[3-oxo-1-decyl]-5-oxocyclopentyl]-hept-5-enoate. 13,14-dihydro-6,15-diketo-19-methyl-PGE<sub>2</sub> ethyl ester is ethyl 7-[(1R,2S,3S)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxocyclopentyl]-6-oxoheptanoate. 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2 $\alpha$</sub>  isopropyl ester is isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[3-oxo-1-decyl]-cyclopentyl]-hept-5-enoate. 13,14-dihydro-15-keto-20-methyl-PGF<sub>2 $\alpha$</sub>  methyl ester is methyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[3-oxo-1-nonyl]-cyclopentyl]-hept-5-enonate.

#### Preferred Compounds

[0020] Preferred prostanoic acid derivatives used in the present invention are those having an oxo group at position 25 15 of the prostanoic acid in place of the hydroxy group as a feature. These derivatives may have a single bond (15-keto-PG<sub>1</sub> compounds), a double bond (15-keto-PG<sub>2</sub> compounds) between positions 5 and 6, or two double bonds (15-keto-PG<sub>3</sub> compounds) between positions 5 and 6 as well as positions 17 and 18.

[0021] Examples of substitution products or derivatives include pharmaceutically or physiologically acceptable salts 30 and esters at the carboxy group at the alpha chain, unsaturated derivatives having a double bond or a triple bond between positions 2 and 3 or positions 5 and 6, respectively, substituted derivatives having substituent(s) on carbon atom(s) at position 3, 6, 16, 17, 19 and/or 20 and compounds having lower alkyl or a hydroxy (lower) alkyl group at position 9 and/or 11 in place of the hydroxy group, of the above PGs.


[0022] Examples of substituents present in preferred compounds are as follows: Substituents on the carbon atom 35 at position 3, 17 and/or 19 include lower alkyl, for example, C<sub>1-4</sub> alkyl, especially methyl and ethyl. Substituents on the carbon atom at position 16 include lower alkyl e.g. methyl, ethyl etc., hydroxy and halogen atom e.g. chlorine, fluorine, aryloxy e.g. trifluoromethylphenoxy, etc. Substituents on the carbon atom at position 20 include saturated and unsaturated lower alkyl e.g. C<sub>1-4</sub> alkyl, lower alkoxy e.g. C<sub>1-4</sub> alkoxy and lower alkoxy (lower) alkyl e.g. C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl. Substituents on the carbon atom at position 6 include oxo group forming carbonyl. Stereochemistry of PGs having hydroxy, lower alkyl or lower (hydroxy) alkyl substituent on the carbon atom at position 9 and/or 11 may be alpha, beta 40 or mixtures thereof.

[0023] Said derivatives may have an alkoxy, phenoxy or phenyl group at the end of the omega chain where the chain is shorter than the primary PGs.

[0024] Especially preferred compounds are those having a lower alkyl such as methyl, ethyl, etc. at position 20.

[0025] A group of preferred compounds used in the present invention has the formula

45



wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least

one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C≡C-, Z is



wherein R<sub>3</sub> is lower alkyl or acyl,

10 R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl,  
R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

[0026] In the above formula, the term "unsaturated" in the definitions for R<sub>1</sub> and R<sub>2</sub> is intended to include at least one and optionally more than one double bond and/or triple bond isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to usual nomenclature, an unsaturation between two serial positions is represented by denoting the lower number of said two positions, and an unsaturation between two distal positions is represented by denoting both of the positions. Preferred unsaturation is a double bond at position 2 and a double or triple bond at position 5.

20 [0027] The term "lower or medium aliphatic hydrocarbon residue" or "medium aliphatic hydrocarbon residue" refers to a straight or branched chain hydrocarbyl group having 1 to 14 carbon atoms or 5 to 14 carbon atoms, respectively, (for a side chain, 1 to 3 carbon atoms being preferred) and preferably 2 to 8 carbon atoms for R<sub>1</sub> and 6 to 9 carbon atoms for R<sub>2</sub>.

[0028] The term "halo" denotes fluoro, chloro, bromo and iodo.

25 [0029] The term "lower" throughout the specification is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.

[0030] The term "lower alkyl" as a group or a moiety in hydroxy(lower)alkyl, monocyclic aryl(lower) alkyl, monocyclic aroyl(lower)alkyl or halo(lower)alkyl includes saturated and straight or branched chain hydrocarbon radicals containing 1 to 6, carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.

30 [0031] The term "lower alkoxy" refers to the group lower-alkyl-O- wherein lower alkyl is as defined above.

[0032] The term "hydroxy(lower)alkyl" refers to lower alkyl as defined above which is substituted with at least one hydroxy group, e.g. hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-1-hydroxyethyl.

[0033] The term "lower alkanoyloxy" refers to a group of the formula: RCO-O- wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, e.g. acetyl.

35 [0034] The term "cyclo(lower)alkyl" refers to a cyclic group formed by cyclization of a lower alkyl group as defined above.

[0035] The term "aryl" includes unsubstituted or substituted aromatic carbocyclic or heterocyclic (preferably monocyclic) groups, e.g. phenyl, tolyl, xylyl and thienyl. Examples of substituents are halo and halo(lower)alkyl wherein halo and lower alkyl being as defined above.

40 [0036] The term "aryloxy" refers to a group of the formula: ArO- wherein Ar is aryl as defined above.

[0037] Suitable "pharmaceutically acceptable salts" includes conventional non-toxic salts, and may be a salt with an inorganic base, for example an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), ammonium salt, a salt with an organic base, for example, an amine salt (e.g. methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)ethane salt, monomethyl-monooethanolamine salt, procaine salt, caffeine salt, etc.), a basic amino acid salt (e.g. arginine salt, lysine salt, etc.), tetraalkyl ammonium salt and the like. These salts can be prepared by the conventional process, for example from the corresponding acid and base or by salt interchange.

45 [0038] Examples of the "pharmaceutically acceptable esters" are aliphatic esters, for example, lower alkyl ester e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester, 1-cyclo-propylethyl ester, etc., lower alkenyl ester e.g. vinyl ester, allyl ester, etc., lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc., hydroxy(lower) alkyl ester e.g. hydroxyethyl ester, lower alkoxy(lower)-alkyl ester e.g. methoxymethyl ester, 1-methoxyethyl ester, etc., and aromatic esters, for example, optionally substituted aryl ester e.g. phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-di-methoxyphenyl ester, benzamidophenyl ester etc., aryl(lower)alkyl ester e.g. benzyl ester, trityl ester, benzhydryl ester, etc. These esters may be prepared by conventional esterification starting from the corresponding acid and alcohol or ester exchange.

50 [0039] Preferred examples of A include -COOH, -COOCH<sub>3</sub>, -COOCH<sub>2</sub>CH<sub>3</sub> and -COOCH(CH<sub>3</sub>)<sub>2</sub>.

[0040] The configuration of the ring and the  $\alpha$ - and/or omega chain in the above formula (I) may be the same as or


different from that in the primary PGs. However, the present invention also includes a mixture of a compound having a primary configuration and that of an unprimary configuration.

[0041] A group of more preferred compounds used in the present invention has the formula

5

10

15



20

wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C≡C-, R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue having 5 or more carbon atoms in the main or straight chain moiety which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

25

[0042] Examples of the typical compounds of the present invention are 15-keto-20-loweralkyl-PGA-Fs and their  $\Delta^2$ -derivatives, 3R,S-methyl-derivatives, 6-oxo-derivatives, 5R,S-fluoro-derivatives, 5,5-difluoro-derivatives, 16R,S-methyl-derivatives, 16,16-dimethyl-derivatives, 16R,S-fluoro-derivatives, 16,16-difluoro-derivatives, 17S-methyl-derivatives, 17R,S-fluoro-derivatives, 17,17-difluoro-derivatives and 19-methyl-derivatives.

30

[0043] The compounds having 15-keto group may be in the keto-hemiacetal equilibrium by forming a hemiacetal between hydroxy group at position 11 and ketone at position 15.

35

[0044] The proportion of both tautomeric isomers, when present, varies depending on the structure of the rest of the molecule or kind of any substituent present and, sometimes, one isomer may predominantly be present in comparison with the other. However, in this invention, it is to be appreciated that the compounds used in the invention include both isomers. Further, while the compounds used in the invention may be represented by a structure or name based on keto-form regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend elimination of the hemiacetal type of compounds.

40

[0045] In the present invention, any of the individual tautomeric isomers, a mixture thereof, or optical isomers, a mixture thereof, a racemic mixture, and other isomers such as steric isomers can be used in the same purpose.

45

[0046] Some of the compounds used in the present invention may be prepared by the method disclosed in Japanese Patent Publications (unexamined) No. A-108/1990 and A-96528/1990.

50

[0047] Alternatively, these compounds may be prepared by a process analogous to that described in the above publications in combination with the known synthetic method for the five-membered ring moiety.

[0048] In the process for preparing 13,14-dihydro-15-keto-compound:


55

A commercially available (-)-Corey lactone, which is used as a starting material, is subjected to Collins oxidation to give an aldehyde. The aldehyde is allowed to react with dimethyl (2-oxoalkyl)phosphonate anion to give an  $\alpha,\beta$ -unsaturated ketone, and the resultant is reduced to ketone. The carbonyl group of the ketone is allowed to react with a diol to give a ketal, thereby protected, then a corresponding alcohol is obtained by elimination of the phenylbenzoyl group, and the resulting hydroxy group is protected with dihydropyran to give a tetrapyranyl ether. Thus, precursors of PGs wherein the  $\omega$ -chain is 13,14-dihydro-15-keto-alkyl can be obtained.

50

[0049] Using the above tetrapyranyl ether as a starting material, 6-keto-PG<sub>1</sub>s of the formula:

55




may be obtained as follows:

The tetrapyranyl ether is reduced using diisobutyl aluminium hydride and the like to give a lactol, which is allowed to react with a ylide obtained from (4-carboxybutyl)triphenylphosphonium bromide, and the resultant is subjected to esterification followed by cyclization, combining the 5,6-double bond and the C-9 hydroxyl group with NBS or iodine, providing a halide. The resultant is subjected to dehydrohalogenation with DBU and the like to give a 6-keto compound, which is subjected to Jones oxidation followed by deprotection to give the objective compound.

5 [0050] Further, PG<sub>2</sub>s of the formula:

10




may be obtained as follows:

15 The above tetrapyranyl ether is reduced to the lactol, which is allowed to react with a ylide obtained from (4-carboxybutyl)triphenylphosphonium bromide to give a carboxylic acid. The resultant is subjected to esterification followed by Jones oxidation and deprotection to give the objective compound.

[0051] In order to obtain PG<sub>1</sub>s of the formula:


20




25

using the above tetrapyranyl ether as a starting material, in the same manner as PG<sub>2</sub> of the formula:

30




40



a monoalkyl copper complex or a dialkyl copper complex of the formula:

45



50

is subjected to 1,4-addition with 4R-t-butyldimethylsilyloxy-2-cyclopenten-1-one, and the resulting copper enolate is seized with 6-carboalkoxy-1-iodo-2-hexyne or a derivative thereof.

[0052] PGs containing a methyl group instead of a hydroxy group at the C-11 position may be obtained as follows: PGA obtained by Jones oxidation of the hydroxy group at the C-9 position of the 11-tosylate is allowed to react with a dimethyl copper complex to give 11-dehydroxy-11-methyl-PGE. Alternatively, an alcohol obtained after elimination of p-phenylbenzoyl group is converted to a tosylate. An unsaturated lactone obtained by DBU treatment of the tosylate is converted to a lactol. After introduction of an  $\alpha$ -chain using Wittig reaction, the resulting alcohol (C-9 position) is oxidized to give PGA. PGA is allowed to react with dimethyl copper complex to give 11-dehydroxy-11-methyl-PGE. The resultant

is reduced using sodium borohydride and the like to give 11-dehydroxy-11-methyl-PGF.

[0053] PGs containing a hydroxymethyl group instead of a hydroxyl group at the C-11 position is obtained as follow: 11-dehydroxy-11-hydroxymethyl-PGE is obtained by a benzophenone-sensitized photoaddition of methanol to PGA. The resultant is, for example, reduced using sodium borohydride to give 11-dehydroxy-11-hydroxymethyl-PGF.

5 [0054] 16-Fluoro-PGs may be obtained using dimethyl (3-fluoro-2-oxoalkyl)phosphonate anion in the preparation of an  $\alpha$ , $\beta$ -unsaturated ketone. Similarly, 19-methyl-PGs may be obtained using a dimethyl (6-methyl-2-oxoalkyl)phosphonate anion.

[0055] The preparations in the present invention are not construed to be limited to them, and suitable means for protection, oxidation, reduction and the like may be employed.

10 [0056] Examples of the preparation of the prostanoic acid compounds are described in the Japanese Patent Publications (unexamined) No. A-151552/1989, A-108/1990, A-96528/1990 and A-96529/1990.

[0057] The  $\beta$ -adrenergic blockers and the prostanoic acid compounds used in the present invention can be used for the treatment of various disease and conditions of humans and animals in which lowering of ocular pressure is desirous and are usually administered systemically or topically by, for example, ophthalmic, oral, intravenous, subcutaneous, 15 rectal administration etc.

[0058] As used herein, the term "treatment" or "treating" refers to any means of control of a disease in a mammal, including preventing the disease, curing the disease, relieving the disease and arresting or relieving the development of the disease.

20 [0059] While the dosage varies depending on the kind, age, weight, condition of the patient, such as humans or animals, severity of the disease, purpose of the treatment, judgement of the physician and route or period of administration, usually a satisfactory effect is obtained within the range of 0.01-500  $\mu$ g/eye of the  $\beta$ -adrenergic blocker and 0.001-500 mg/kg of the prostanoic acid compound.

[0060] The agents used in the present invention can be administered in the form of a pharmaceutical composition containing the active components and optionally other ingredients, such as carrier, diluent or excipient.

25 [0061] Such composition includes liquids such as ophthalmic solution, emulsion, dispersion etc. and semisolids such as gel, ointment etc.

[0062] Diluents for the aqueous solution or suspension include, for example, distilled water and physiological saline. Diluents for the nonaqueous solution and suspension include, for example, vegetable oils e.g. olive oil, liquid paraffine, mineral oil, and propylene glycol and p-octyldodecanol. The composition may also contain isotonicization agents such as sodium chloride, boric acid, sodium citrate, etc. to make isotonic with the lacrimal fluid and buffering agents such as borate buffer, phosphate buffer, etc. to maintain pH about 5.0 to 8.0. Further, stabilizers such as sodium sulfite, propylene glycol, etc., chelating agents such as sodium edetate, etc., thickeners such as glycerol, carboxymethylcellulose, carboxyvinyl polymer, etc. and preservatives such as methyl paraben, propyl paraben, etc. may also be added. these can be sterilized e.g. by passing through a bacterial filter or by heating.

35 [0063] The ophthalmic ointment may contain vaseline, Plastibase, Macrogol, etc. as a base and surfactant for increasing hydrophilicity. It may also contain gelling agents such as carboxymethylcellulose, methylcellulose, carboxyvinyl polymer, etc.

[0064] In addition, the composition may contain antibiotics such as chloramphenicol, penicillin, etc. in order to prevent or treat bacterial infection.

40 [0065] These composition may be packaged with an indication for administration. Such indication may be printing on package box, a bottle, a label, a separate paper sheet etc.

[0066] A more complete understanding of the present invention can be obtained by reference to the following Preparation Examples, Formulation Examples and Test Examples which are provided herein for purpose of illustration only and are not intended to limit the scope of the invention.

45

### Preparations

[0067] Preparations of 13,14-dihydro-15-keto-20-ethyl-PGA<sub>2</sub> isopropyl ester, 13,14-dihydro-15-keto-20-ethyl-PGE<sub>2</sub> isopropyl ester and 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2</sub> $\alpha$  isopropyl ester (cf. Preparation chart I):

50

1) Preparation of 1S-2-oxa-3-oxo-6R-(3-oxo-1-trans-decenyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo[3.3.0]-octane (3):

Commercially available (-)-Corey lactone (1) (7 g) was subjected to Collins oxidation in dichloromethane to give aldehyde (2). The resultant was allowed to react with dimethyl (2-oxononyl)phosphonate (4.97 g) anion to give 1S-2-oxa-3-oxo-6R-(3,3-ethylendioxy-1-trans-decenyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo[3.3.0]-octane (3).

55 2) Preparation of 1S-2-oxa-3-oxo-6R-(3-oxodecyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo[3.3.0]-octane (4):  
Unsaturated ketone (3) (7.80 g) was reduced in ethyl acetate (170 ml) using 5% Pd/C under hydrogen atmos-

phere. The product obtained after the usual work-up (4) was used in the following reaction.

3) Preparation of 1S-2-oxa-3-oxo-6R-(3,3-ethylenedioxy-decyl)-7R-(4-phenylbenzoyloxy)-cis-bicyclo[3.3.0]-octane (5):

Saturated ketone (4) was converted to ketal (5) in dry benzene (150 ml) using ethylene glycol and p-toluenesulfonic acid (catalytic amount).

4) Preparation of 1S-2-oxa-3-oxo-6R-(3,3-ethylenedioxy-decyl)-7R-hydroxy-cis-bicyclo[3.3.0]-octane (6):

To a solution of ketal (5) in absolute methanol (150 ml) was added potassium carbonate (2.73 g). The mixture was stirred overnight at room temperature. After neutralization with acetic acid, the resultant was concentrated under reduced pressure. The resulting crude product was extracted with ethyl acetate. The organic layer was washed with a dilute aqueous solution of sodium bicarbonate and a saline, and dried. The crude product obtained after evaporation was chromatographed to give alcohol (6). Yield: 3.31 g

5) Preparation of lactol (7):

Alcohol (6) (0.80 g) was reduced in dry toluene (8 ml) using DIBAL-H at -78 °C to give lactol (7).

6) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2</sub>α (8):

A DMSO solution of lactol (7) was added to ylide prepared from (4-carboxybutyl)triphenylphosphonium bromide (3.65 g). The reaction mixture was stirred overnight to give carboxylic acid (8).

7) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2</sub>α isopropyl ester (9):

Carboxylic acid (8) was converted to 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2</sub>α isopropyl ester (9) using DBU and isopropyl iodide in acetonitrile.

Yield: 0.71 g

8) Preparation of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2</sub>α isopropyl ester (10):

13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2</sub>α isopropyl ester (9) (0.71 g) was kept in acetic acid/THF/water (3/1/1) at 40 °C for 3 hours. The crude product obtained after concentration under reduced pressure was chromatographed to give 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2</sub>α isopropyl ester (10).

Yield: 0.554 g

9) Preparation of 13,14-dihydro-15-keto-20-ethyl-PGA<sub>2</sub>α isopropyl ester (12):

A solution of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2</sub>α isopropyl ester (10) (0.125 g) and p-toluenesulfonyl chloride (0.112 g) in pyridine (5 ml) was maintained at 0 °C for 2 days. According to the usual work-up, tosylate (11) was obtained.

Tosylate (11) was subjected to Jones oxidation in acetone (8 ml) at -25 °C. The crude product obtained after the usual work-up was chromatographed to give 13,14-dihydro-15-keto-20-ethyl-PGA<sub>2</sub>α isopropyl ester (2).

Yield: 0.060 g

10) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGF<sub>2</sub>α isopropyl ester (13):

13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF<sub>2</sub>α isopropyl ester (9) (3.051 g) was dissolved in dry N,N-dimethylformamide (25 ml), t-butyldimethylsilyl chloride (1.088 g) and imidazole (0.49 g) was added thereto. The resultant was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was chromatographed to give 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGF<sub>2</sub>α isopropyl ester (13).

Yield: 2.641 g

11) Preparation of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGE<sub>2</sub> isopropyl ester (14):

13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGF<sub>2</sub>α isopropyl ester (13) (1.257 g) was subjected to Jones oxidation at -40 °C. After the usual work-up, the resulting crude product was chromatographed to give 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGE<sub>2</sub> isopropyl ester (14).


Yield: 1.082 g

12) Preparation of 13,14-dihydro-15-keto-20-ethyl-PGE<sub>2</sub> isopropyl ester (15):


To a solution of 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-11-t-butyldimethylsiloxy-PGE<sub>2</sub> isopropyl ester (14) in acetonitrile was added hydrofluoric acid (46% aqueous solution). The mixture was stirred at room temperature for 40 minutes. The crude products obtained after usual work-up was chromatographed to give 13,14-dihydro-15-keto-20-ethyl-PGE<sub>2</sub> isopropyl ester (15).

Yield: 0.063 g (97%)


5



10




20




Preparation Clarte

25


↓



30




35



40

45

↓



50

55

## Preparation Chart (continued)

5

10

15

20

25

30





35

40

45

50

55



+ : isopropyl

5

Formulation Example 1		
Timolol maleate	0.1 g	
Physiological saline	q.s. to 100 ml	

10

Formulation Example 2		
13,14-dihydro-15-keto-20-ethyl-PGF <sub>2</sub> $\alpha$ isopropyl ester	0.01 g	
Nonion Surfactant	1.0 g	
Physiological saline	q.s. to 100 ml	

20

Test Example 1

15

[0068] Hypotensive effect of Timolol was evaluated in the enhancement phase of aqueous humour production and the suppression phase of aqueous humour production of rabbits. Since the circadian rhythm of rabbits, different from that of humans, has the enhancement phase of aqueous humour production at night and the suppression phase of aqueous humour production at daytime, the following two experiments were performed.

25

(1) Enhancement phase of aqueous humour production:

25

[0069] White rabbits (n=8) were used in the experiment of intraocular pressure measurement after keeping under the environmental conditions including a light and darkness cycle consisting of a light period from 21:00 to 9:00 and a dark period from 9:00 to 21:00 for more than one week. In the experiment, 35  $\mu$ l of a 0.5% Timolol eyedrop (Trademark: Timoptol) was administered to one eye at 11:00 (dark time). The ocular tension was measured immediately before and 1 hour after the administration and the difference between the obtained two values was expressed as decrease in intraocular pressure ( $\Delta$ IOP).

30

(2) Suppression phase of aqueous humour production:

35

[0070] White rabbits (n=12) were used in the experiment of intraocular pressure measurement after keeping under the environmental conditions including a light and darkness cycle consisting of a light period from 8:00 to 20:00 and a dark period from 20:00 to 8:00 for more than one week. In the experiment, 35  $\mu$ l of a 0.5% Timolol eyedrop (Trademark: Timoptol) was administered to one eye at 10:00 (light time). The ocular tension was measured immediately before and 3 hours after the administration and the difference between the obtained two values was expressed as decrease in intraocular pressure ( $\Delta$ IOP). The results are shown in Table 1.

Table 1

40

	Enhancement Phase*	Suppression Phase*
$\Delta$ IOP (mmHg)	6.4 $\pm$ 1.0	2.5 $\pm$ 0.8

\* Production of aqueous humour

45

[0071] Then, the procedure of the experiment (2) was repeated except that a 0.12% eye drop of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2</sub> $\alpha$  isopropyl ester was used in place of the 0.5% Timolol eye drop. The results are shown in Table 2.

Table 2

50

	Suppression Phase*
$\Delta$ IOP (mmHg)	7.1 $\pm$ 0.7

\* See footnote of Table 1.

55

Test Example 2

[0072] A 0.5% Timolol eye drop was intraocularly administered to subjects of glaucoma (n=8) twice (morning and evening) a day for 4 weeks. Differences in intraocular pressure were measured as in Test Example 1 and expressed

as decrease in intraocular pressure ( $\Delta$ IOP). The results are shown in Table 3.

Table 3

	Enhancement Phase* (11:00)	Suppression Phase* (19:00)
$\Delta$ IOP (mmHg)	2.9±0.8	0.4±0.7

\* See footnote of Table 1.

[0073] Separately, the above experiment was repeated using subjects of glaucoma (n=10) and administering a 0.12% eye drop of 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2</sub> $\alpha$  isopropyl ester in place of the 0.5% Timolol eye drop and decrease in intraocular pressure ( $\Delta$ IOP) was determined at the suppression phase of aqueous humour production (19:00). The results are shown in Table 4.


Table 4

	Suppression Phase*
$\Delta$ IOP (mmHg)	2.1±0.3

\* See footnote of Table 1.

## Claims


1. The use of a  $\beta$ -adrenergic blocker and of a derivative of prostanoic acid for the manufacture of a therapeutic kit for the concomitant treatment of ocular hypertension, wherein the  $\beta$ -adrenergic blocker is to be administered only in the enhancement phase of aqueous humour production and the derivative of prostanoic acid is to be administered only in the suppression phase of aqueous humour production.
2. The use according to claim 1 wherein the derivative of prostanoic acid is represented by the following formula (I): -



wherein

X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C≡C-,

Z is



wherein R<sub>3</sub> is lower alkyl or acyl,


$R_1$  is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl,

$R_2$  is saturated or unsaturated, medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

5

3. The use according to claim 1 wherein the derivative of prostanoic acid is represented by the following formula (II):-

10



15

20

25

wherein

X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-,

30

-CH=CH- or -C≡C-, R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue having 5 or more carbon atoms in the main or straight chain moiety which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

35

4. The use according to claim 3 wherein the derivative of prostanoic acid is 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester.

40

5. The use according to any one of claims 1 to 3 wherein the derivative of prostanoic acid is a prostaglandin.

6. The use according to claim 5 wherein the derivative of prostanoic acid is a prostaglandin F.

45

7. The use according to claim 5 wherein the derivative of prostanoic acid is a 15-keto-prostaglandin.


8. The use according to any one of claims 1 to 7 wherein the β-adrenergic blocker is selected from the group consisting of Timolol, Befunolol, Betaxolol, Levobunolol, Carteolol and pharmaceutically acceptable salts thereof.

50

9. The use of a β-adrenergic blocker and of a derivative of prostanoic acid for the manufacture of a therapeutic kit for the concomitant treatment of glaucoma, wherein the β-adrenergic blocker is to be administered only in the enhancement phase of aqueous humour production and the derivative of prostanoic acid is to be administered only in the suppression phase of aqueous humour production.

55


10. The use according to claim 9 wherein the derivative of prostanoic acid is represented by the following formula (I): -



wherein

20 X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C≡C-,

Z is




30 wherein R<sub>3</sub> is lower alkyl or acyl,

R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl,

R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

35 11. The use according to claim 9 wherein the derivative of prostanoic acid is represented by the following formula (II): -



wherein

55 X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, A is -COOH or its pharmaceutically acceptable salt or ester, B is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- or -C≡C-, R<sub>1</sub> is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo

or aryl, R<sub>2</sub> is saturated or unsaturated, medium aliphatic hydrocarbon residue having 5 or more carbon atoms in the main or straight chain moiety which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, aryl or aryloxy.

5 12. The use according to claim 11 wherein the derivative of prostanoic acid is 13,14-dihydro-15-keto-20-ethyl-PGF<sub>2α</sub> isopropyl ester.

13. The use according to any one of claims 9-11 wherein the derivative of prostanoic acid is a prostaglandin.

10 14. The use according to claim 13 wherein the derivative of prostanoic acid is a prostaglandin F.

15 15. The use according to claim 13 wherein the derivative of prostanoic acid is a 15-keto-prostaglandin.

16. The use according to any one of claims 9 to 15 wherein the β-adrenergic blocker is selected from the group consisting of Timolol, Befunolol, Betaxolol, Levobunolol, Carteolol and pharmaceutically acceptable salts thereof.

17. The use according to any preceding claim wherein the enhancement phase is in the daytime and the suppression phase is at night.


20

#### Patentansprüche

1. Verwendung eines β-adrenergen Blockers und eines Derivats von Prostansäure zur Herstellung eines therapeutischen Kits für die gleichzeitige bzw. begleitende Behandlung von Augenhochdruck, wobei der β-adrenerge Blocker nur in der Verstärkungsphase der Kammerwasserproduktion verabreicht werden soll und das Derivat der Prostansäure nur in der Unterdrückungsphase der Kammerwasserproduktion verabreicht werden soll.

2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das Derivat der Prostansäure durch die folgende allgemeine Formel (I) angegeben wird:


30



worin

X und Y für Wasserstoff, Hydroxy, Halogen, Niedrigalkyl, Hydroxy(niedrig)alkyl oder Oxo stehen, mit der Maßgabe, dass mindestens eines von X und Y eine andere Gruppe als Wasserstoff ist, wobei der 5-gliedrige Ring mindestens eine Doppelbindung haben kann, A für -COOH oder das pharmazeutische Salz oder den pharmazeutischen Ester davon steht, B für -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH oder -C≡C steht,  
Z für

55




steht,

wobei  $R_3$  die Bedeutung Niedrigalkyl oder Acyl hat,

$R_1$  für einen zweiwertigen gesättigten oder ungesättigten, niederen oder mittleren aliphatischen Kohlenwasserstoffrest, der unsubstituiert ist oder mit Halogen, Oxo oder Aryl substituiert ist, steht,

$R_2$  für einen gesättigten oder ungesättigten mittleren aliphatischen Kohlenwasserstoffrest, der unsubstituiert ist oder mit Halogen, Hydroxy, Oxo, Niedrigalkoxy, Niedrigalkanoyloxy, Cyclo(niedrig)alkyl, Aryl oder Aryloxy substituiert ist, steht.

3. Verwendung nach Anspruch 1, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure durch die folgende Formel (II):



angegeben wird,

worin

$X$  und  $Y$  für Wasserstoff, Hydroxy, Halogen, Niedrigalkyl, Hydroxy(niedrig)alkyl oder Oxo stehen, mit der Maßgabe, dass mindestens eines von  $X$  und  $Y$  eine andere Gruppe als Wasserstoff ist, wobei der 5-gliedrige Ring mindestens eine Doppelbindung haben kann,  $A$  für  $-COOH$  oder das pharmazeutische Salz oder den pharmazeutischen Ester davon steht,  $B$  für  $-CH_2-CH_2-$ ,  $-CH=CH$  oder  $-C\equiv C$  steht,  $R_1$  für einen zweiwertigen gesättigten oder ungesättigten niederen oder mittleren aliphatischen Kohlenwasserstoffrest, der unsubstituiert ist oder mit Halogen, Oxo oder Aryl substituiert ist, steht,

$R_2$  für einen gesättigten oder ungesättigten, mittleren aliphatischen Kohlenwasserstoffrest mit 5 oder mehr Kohlenstoffatomen in der Hauptkette oder der geradkettigen Gruppierung, der unsubstituiert ist oder mit Halogen, Hydroxy, Oxo, Niedrigalkoxy, Niedrigalkanoyloxy, Cyclo(niedrig)alkyl, Aryl oder Aryloxy substituiert ist, steht.

4. Verwendung nach Anspruch 3, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure der 13,14-Dihydro-15-keto-20-ethyl-PGF<sub>2 $\alpha$</sub> -isopropylester ist.

5. Verwendung nach einem der Ansprüche 1 bis 3, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure Prostaglandin ist.

6. Verwendung nach Anspruch 5, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure Prostaglandin F ist.

7. Verwendung nach Anspruch 5, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure ein 15-Ketoprostaglandin ist.

8. Verwendung nach einem der Ansprüche 1 bis 7, **dadurch gekennzeichnet, dass** der  $\beta$ -adrenerge Blocker aus der Gruppe, bestehend aus Timolol, Befunolol, Betaxolol, Levobunolol, Carteolol und den pharmazeutisch annehmbaren Salzen davon ausgewählt wird.

9. Verwendung eines  $\beta$ -adrenergen Blockers und eines Derivats der Prostansäure zur Herstellung eines therapeutischen Kits für die gleichzeitige bzw. begleitende Behandlung des Glaukoms, wobei der  $\beta$ -adrenerge Blocker nur in der Verstärkungsphase der Kammerwasserproduktion verabreicht werden soll und das Derivat der Prostansäure

nur in der Unterdrückungsphase der Kammerwasserproduktion verabreicht werden soll.


10. Verwendung nach Anspruch 9, dadurch gekennzeichnet, dass das Derivat der Prostansäure durch die folgende allgemeine Formel (I) angegeben wird:

5

10

15

20




worin

25 X und Y für Wasserstoff, Hydroxy, Halogen, Niedrigalkyl, Hydroxy(niedrig)alkyl oder Oxo stehen, mit der Maßgabe, dass mindestens eines von X und Y eine andere Gruppe als Wasserstoff ist, wobei der 5-gliedrige Ring mindestens eine Doppelbindung haben kann, A für -COOH oder das pharmazeutische Salz oder den pharmazeutischen Ester davon steht, B für -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH oder -C≡C steht,

Z für

30



35

steht,

wobei R<sub>3</sub> die Bedeutung Niedrigalkyl oder Acyl hat,


40 R<sub>1</sub> für einen zweiwertigen gesättigten oder ungesättigten, niederen oder mittleren aliphatischen Kohlenwasserstoffrest, der unsubstituiert ist oder mit Halogen, Oxo oder Aryl substituiert ist, steht,

R<sub>2</sub> für einen gesättigten oder ungesättigten mittleren aliphatischen Kohlenwasserstoffrest, der unsubstituiert ist oder mit Halogen, Hydroxy, Oxo, Niedrigalkoxy, Niedrigalkanoyloxy, Cyclo(niedrig)alkyl, Aryl oder Aryloxy substituiert ist, steht.

45 11. Verwendung nach Anspruch 9, dadurch gekennzeichnet, dass das Derivat der Prostansäure durch die folgende Formel (II):

50

55



angegeben wird,  
worin

20 X und Y für Wasserstoff, Hydroxy, Halogen, Niedrigalkyl, Hydroxy(niedrig)alkyl oder Oxo stehen, mit der Maßgabe, dass mindestens eines von X und Y eine andere Gruppe als Wasserstoff ist, wobei der 5-gliedrige Ring mindestens eine Doppelbindung haben kann, A für -COOH oder das pharmazeutische Salz oder den pharmazeutischen Ester davon steht, B für -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH oder -C≡C steht, R<sub>1</sub> für einen zweiwertigen gesättigten oder ungesättigten niederen oder mittleren aliphatischen Kohlenwasserstoffrest, der unsubstituiert ist oder mit Halogen, Oxo oder Aryl substituiert ist, steht,

25 R<sub>2</sub> für einen gesättigten oder ungesättigen, mittleren aliphatischen Kohlenwasserstoffrest mit 5 oder mehr Kohlenstoffatomen in der Hauptkette oder der geradkettigen Gruppierung, der unsubstituiert ist oder mit Halogen, Hydroxy, Oxo, Niedrigalkoxy, Niedrigalkanoyloxy, Cyclo(niedrig)alkyl, Aryl oder Aryloxy substituiert ist, steht.

30 12. Verwendung nach Anspruch 11, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure 13,14-Dihydro-15-keto-20-ethyl-PGF<sub>2α</sub>-Isopropylester ist.

35 13. Verwendung nach einem der Ansprüche 9 bis 11, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure Prostaglandin ist.

40 14. Verwendung nach Anspruch 13, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure ein Prostaglandin F ist.

45 15. Verwendung nach Anspruch 13, **dadurch gekennzeichnet, dass** das Derivat der Prostansäure 15-Ketoprostaglandin ist.

50 16. Verwendung nach einem der Ansprüche 9 bis 15, **dadurch gekennzeichnet, dass** der β-adrenerge Blocker aus der Gruppe, bestehend aus Timolol, Befunolol, Betaxolol, Levobunolol, Carteolol und den pharmazeutisch annehmbaren Salzen davon, ausgewählt wird.

55 17. Verwendung nach einem der vorstehenden Ansprüche, **dadurch gekennzeichnet, dass** die Verstärkungsphase tagsüber erfolgt und dass die Unterdrückungsphase über Nacht erfolgt.

#### Revendications


50 1. Utilisation d'un inhibiteur β-adrénergique et d'un dérivé d'acide prostanoïque pour la fabrication d'une trousse thérapeutique destinée au traitement concomitant de l'hypertension oculaire, dans laquelle l'inhibiteur β-adrénergique n'est à administrer que dans la phase de stimulation de la production d'humeur aqueuse et le dérivé d'acide prostanoïque n'est à administrer que dans la phase de freinage de la production d'humeur aqueuse.

55 2. Utilisation selon la revendication 1 dans laquelle le dérivé d'acide prostanoïque est représenté par la formule (I) suivante:

5

10

15




dans laquelle

X et Y sont des atomes d'hydrogène ou des groupes hydroxy, halogéno, alkyle inférieur, hydroxyalkyle inférieur ou oxo, à condition qu'au moins un des radicaux X et Y soit un groupe autre qu'un atome d'hydrogène, et le noyau à 5 chainons peut comporter au moins une double liaison, A est -COOH ou son sel ou ester pharmaceutiquement acceptable, B est -CH<sub>2</sub>-CH<sub>2</sub>- ou -CH=CH- ou -C≡C-,

Z est

25

où R<sub>3</sub> est un groupe alkyle inférieur ou acyle,

30

R<sub>1</sub> est un résidu hydrocarboné aliphatique bivalent, inférieur ou moyen, saturé ou insaturé, qui est non substitué ou substitué par un groupe halogéno, oxo ou aryle,

R<sub>2</sub> est un résidu hydrocarboné aliphatique moyen, saturé ou insaturé, qui est non substitué ou substitué par un groupe halogéno, hydroxy, oxo, alcoxy inférieur, alcanoxy, cycloalkyle inférieur, aryle ou aryloxy.


35

3. Utilisation selon la revendication 1 dans laquelle le dérivé d'acide prostanoïque est représenté par la formule (II) suivante:

40

45

50



dans laquelle

55

X et Y sont des atomes d'hydrogène ou des groupes hydroxy, halogéno, alkyle inférieur, hydroxyalkyle inférieur ou oxo, à condition qu'au moins un des radicaux X et Y soit un groupe autre qu'un atome d'hydrogène, et le noyau à 5 chainons peut comporter au moins une double liaison, A est -COOH ou son sel ou ester pharmaceutiquement acceptable, B est -CH<sub>2</sub>-CH<sub>2</sub>- ou -CH=CH- ou -C≡C-, R<sub>1</sub> est un résidu hydrocarboné aliphatique bivalent, inférieur

ou moyen, saturé ou insaturé, qui est non substitué ou substitué par un groupe halogéno, oxo ou aryle, R<sub>2</sub> est un résidu hydrocarboné aliphatique moyen, saturé ou insaturé, comportant au moins 5 atomes de carbone dans le groupement principal ou à chaîne linéaire, qui est non substitué ou substitué par un groupe halogéno, hydroxy, oxo, alcoxy inférieur, alcanoyloxy inférieur, cycloalkyle inférieur, aryle ou aryloxy.

5      4. Utilisation selon la revendication 3 dans laquelle le dérivé d'acide prostanoïque est l'ester isopropylique de 13,14-dihydro-15-céto-20-éthyl-PGF<sub>2α</sub>.

10     5. Utilisation selon l'une quelconque des revendications 1 à 3 dans laquelle le dérivé d'acide prostanoïque est une prostaglandine.


15     6. Utilisation selon la revendication 5 dans laquelle le dérivé d'acide prostanoïque est une prostaglandine F.

7. Utilisation selon la revendication 5 dans laquelle le dérivé d'acide prostanoïque est une 15-céto-prostaglandine.

15     8. Utilisation selon l'une quelconque des revendications 1 à 7 dans laquelle l'inhibiteur β-adrénergique est choisi dans le groupe constitué par le Timolol, le Béfunolol, le Bétaxolol, le Lévobunolol, le Cartéolol et leurs sels pharmaceutiquement acceptables.

20     9. Utilisation d'un inhibiteur β-adrénergique et d'un dérivé d'acide prostanoïque pour la fabrication d'une trousse thérapeutique destinée au traitement concomitant du glaucome, dans laquelle l'inhibiteur β-adrénergique n'est à administrer que dans la phase de stimulation de la production d'humeur aqueuse et le dérivé d'acide prostanoïque n'est à administrer que dans la phase de freinage de la production d'humeur aqueuse.

25     10. Utilisation selon la revendication 9 dans laquelle le dérivé d'acide prostanoïque est représenté par la formule (I) suivante:



dans laquelle

X et Y sont des atomes d'hydrogène ou des groupes hydroxy, halogéno, alkyle inférieur, hydroxyalkyle inférieur ou oxo, à condition qu'au moins un des radicaux X et Y soit un groupe autre qu'un atome d'hydrogène, et le noyau à 5 chaînons peut comporter au moins une double liaison, A est -COOH ou son sel ou ester pharmaceutiquement acceptable, B est -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH- ou -C≡C-,

50     Z est




où R<sub>3</sub> est un groupe alkyle inférieur ou acyle,

5  $R_1$  est un résidu hydrocarboné aliphatique bivalent, inférieur ou moyen, saturé ou insaturé, qui est non substitué ou substitué par un groupe halogéno, oxo ou aryle,

$R_2$  est un résidu hydrocarboné aliphatique moyen, saturé ou insaturé, qui est non substitué ou substitué par un groupe halogéno, hydroxy, oxo, alcoxy inférieur, alcanoxy inférieur, cycloalkyle inférieur, aryle ou aryloxy.

10 11. Utilisation selon la revendication 9 dans laquelle le dérivé d'acide prostanoïque est représenté par la formule (II) suivante:



dans laquelle

30  $X$  et  $Y$  sont des atomes d'hydrogène ou des groupes hydroxy, halogéno, alkyle inférieur, hydroxyalkyle inférieur ou oxo, à condition qu'au moins un des radicaux  $X$  et  $Y$  soit un groupe autre qu'un atome d'hydrogène, et le noyau à 5 chainons peut comporter au moins une double liaison, A est -COOH ou son sel ou ester pharmaceutiquement acceptable, B est  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$  ou  $-\text{C}\equiv\text{C}-$ ,  $R_1$  est un résidu hydrocarboné aliphatique bivalent, inférieur ou moyen, saturé ou insaturé, qui est non substitué ou substitué par un groupe halogéno, oxo ou aryle,  $R_2$  est un résidu hydrocarboné aliphatique moyen, saturé ou insaturé, comportant au moins 5 atomes de carbone dans le groupement principal ou à chaîne linéaire, qui est non substitué ou substitué par un groupe halogéno, hydroxy, oxo, alcoxy inférieur, alcanoxy inférieur, cycloalkyle inférieur, aryle ou aryloxy.

35 12. Utilisation selon la revendication 11 dans laquelle le dérivé d'acide prostanoïque est l'ester isopropylque de 13,14-dihydro-15-céto-20-éthyl-PGF<sub>2 $\alpha$</sub> .

13. Utilisation selon l'une quelconque des revendications 9 à 11 dans laquelle le dérivé d'acide prostanoïque est une prostaglandine.

40 14. Utilisation selon la revendication 13 dans laquelle le dérivé d'acide prostanoïque est une prostaglandine F.

15. Utilisation selon la revendication 13 dans laquelle le dérivé d'acide prostanoïque est une 15-céto-prostaglandine.

45 16. Utilisation selon l'une quelconque des revendications 9 à 15 dans laquelle l'inhibiteur  $\beta$ -adrénergique est choisi dans le groupe constitué par le Timolol, le Béfunolol, le Bétaxolol, le Lévobunolol, le Cartéolol et leurs sels pharmaceutiquement acceptables.

50 17. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle la phase de stimulation est dans la journée et la phase de freinage est la nuit.